Aluminum Phosphate
Phase 3Biologic
Aluminum phosphate is used as an ingredient in vaccines to help the body's immune system respond better to the vaccine, and it's also used as an antacid to relieve heartburn and stomach upset.[1] Aluminum Phosphate is currently being investigated across 5 indications[3], with its most advanced program in Phase 3.[1]
Aluminum Phosphate is one of 136 biologic programs targeting Plasmodium falciparum malaria. It is currently in Phase 3.
5
Indications
24
Total Trials
2
Active Trials
135
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
479 competitors in Malaria
#DrugCompanyPhaseTrials
1Aluminum Phosphate
NNational Institute of Allergy and Infectious Diseases (NIAID)
Phase 3
Biltricide
BayerPreclinical
Stelara
Johnson & JohnsonPreclinical
Hydroxychloroquine Sulfate
NovartisPreclinical
Iron
WWatson Pharmaceuticals
Preclinical
IV LBH589
NovartisPreclinical
IV Ceftriaxone
RRESnTEC, Institute of Research
Preclinical
Mefloquine Plus Artesunate
Medicines for Malaria VenturePreclinical
RTS,S/AS01E
GSKPreclinical
Malarone
Medicines for Malaria VenturePreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Immunogenicity8 trials
A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of MN Recombinant Soluble gp120/HIV-1 (rsgp120/HIV-1) (Genentech) in Combination With QS21 Adjuvant and/or Alum in Healthy Adults
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00001052·110 enrolled
A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of rgp120/HIV-1MN (Genentech) in Combination With QS21 Adjuvant and/or Alum in Healthy Adults.
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00001044·80 enrolled
Show 5 more trials
A Phase I Safety and Immunogenicity Study of HIV p17/p24:Ty-VLP in HIV-1 Seronegative Subjects
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00001053·36 enrolled
A Phase I, Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Compare the Safety and Immunogenicity of Recombinant Envelope Protein rgp120/HIV-1SF2 (BIOCINE) Combined With Seven Adjuvants in Healthy HIV-1 Uninfected Individuals
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00001042·112 enrolled
Effectiveness3 trials
The Effectiveness of Human Antibodies in Influencing an AIDS-Like Disease in Monkeys
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00031109·10 enrolled
Adult2 trials
Phase I STEBVax in Healthy Adults
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00974935·29 enrolled
Dose-Escalating Trial Using Vero Cell-culture Derived H5N1 +/- Aluminum in Adults
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00382980·308 enrolled
Malaria1 trial
Safety and Immunogenicity of EBA-175 RII-NG Malaria Vaccine Administered Intramuscularly
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00347555·80 enrolled
Adjuvant1 trial
H5 Vaccine Alone or With Adjuvant in Healthy Adults
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1/2·NCT00296634·600 enrolled
9 more indications
Flu Vaccine1 trial
H5 Adult - Chiron Study of Bird Flu Vaccine
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1/2·NCT00280033·394 enrolled
Thyroid1 trial
Type 1 Diabetes1 trial
Subarachnoid Hemorrhage1 trial
Dapsone Use in Patients With Aneurysmal Subarachnoid Hemorrhage.
Completed·EEl Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez·Phase 3·NCT05131295·49 enrolled
HIV-11 trial
Vaccine1 trial
H5 Vaccine Alone or With Aluminum Hydroxide in Elderly Adults
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1/2·NCT00294099·600 enrolled
COVID-191 trial
A Phase 1, Open-Label, Safety and Immunogenicity Trial of Boost-2867, an IgG-Fc-RBD Fusion Protein Next Generation SARS-CoV-2 Booster Vaccine, Via Intranasal and Intramuscular Routes in Previously Vaccinated Adults
Active, not recruiting·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT07221162·140 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Aluminum Phosphate. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details